2027 ICD-10-CM Diagnosis Code QA1.790Familial cancer syndrome with pathogenic BRCA1 mutation

ICD-10-CM Codes›Q00-Q99›QA0-QA1›QA1

ICD-10-CM QA1.790
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

QA1.790 is a billable ICD-10-CM diagnosis code for familial cancer syndrome with pathogenic BRCA1 mutation. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 951. The code is exempt from POA reporting.

Code Identity

ICD-10-CM Code
QA1.790
Billable Status
Yes — Valid for Submission
Code Describes
Familial cancer syndrome with pathogenic BRCA1 mutation
Short Description
Familial cancer syndrome with pathogenic BRCA1 mutation
Same as the full description in the CMS dataset.
Parent Code
QA1.79
Other inherited neoplasm predisposition syndrome of multiple systems

Code Classification

ChapterQ00-Q99Congenital malformations, deformations and chromosomal abnormalities
SectionQA0-QA1Genetic disorders, not elsewhere classified
CategoryQA1Genetic disorders associated with neoplasms, not elsewhere classified
This CodeQA1.790Familial cancer syndrome with pathogenic BRCA1 mutation

Present on Admission (POA)Billing

QA1.790 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review the other POA exempt codes in Genetic disorders, not elsewhere classified (QA0-QA1).

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to QA1.790: its own notes plus those printed at QA1 and Chapter 17. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • BRCA1-cancer predisposition syndrome
  • Hereditary breast and ovarian cancer syndrome with pathogenic BRCA1 mutation

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From QA1 Genetic disorders associated with neoplasms, not elsewhere classified applies to 5 codes
  • multiple endocrine neoplasia [MEN] syndromes (E31.2-)
From Chapter 17 (Q00-QA1) Congenital malformations, deformations and chromosomal abnormalities applies to 900 codes
  • inborn errors of metabolism (E70-E88)

Code Also

A second code may be needed to fully describe the condition; the note gives no sequencing direction.

From QA1 Genetic disorders associated with neoplasms, not elsewhere classified applies to 5 codes
  • if applicable, any associated conditions, such as:
  • genetic susceptibility to malignant neoplasm by site (Z15.0-)
  • malignant neoplasms (C00.0-C96.9)
  • personal history of malignant neoplasm (Z85.-)

Notes

General instructions on how these codes are used.

From Chapter 17 (Q00-QA1) Congenital malformations, deformations and chromosomal abnormalities applies to 900 codes
  • Codes from this chapter are not for use on maternal records

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Code History & ChangesHistory

New Code QA1.790 was added to the ICD-10-CM code set for FY 2027, effective October 1, 2026.

FY 2027AddedAdded to the ICD-10-CM code setEffective October 1, 2026.
FY 2027CurrentRevised in the current code setEffective October 1, 2026 through September 30, 2027.

Questions About QA1.790Overview

What is the ICD-10 code for familial cancer syndrome with pathogenic BRCA1 mutation?

The ICD-10-CM code for familial cancer syndrome with pathogenic BRCA1 mutation is QA1.790 (sometimes written as QA1790). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is QA1.790 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report familial cancer syndrome with pathogenic BRCA1 mutation on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does QA1.790 group to?

When familial cancer syndrome with pathogenic BRCA1 mutation is the principal diagnosis on an inpatient stay, it groups to MS-DRG 951 (other Factors Influencing Health Status), which carries a relative weight of 0.5574. Higher weights mean higher Medicare reimbursement.

Is QA1.790 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for familial cancer syndrome with pathogenic BRCA1 mutation on inpatient claims. The code appears in the Genetic disorders, not elsewhere classified (QA0-QA1) range of the CMS exempt list.